1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Alberto Abaterusso
Alberto Abaterusso
Articles (1253) 

Amgen Declares Quarterly Dividend

The company will pay $1.32 per share on June 8

March 08, 2018 | About:

U.S. global pharmaceutical company Amgen Inc. (NASDAQ:AMGN) has authorized the payment of a quarterly dividend for the second quarter of fiscal 2018. The company says it will pay its shareholders a cash dividend of $1.32 per share.

Shareholders of Amgen will pocket the quarterly free cash flow distribution on June 8. The recipient must be on the company’s dividend record no later than May 17 to benefit. The ex-dividend date is scheduled for May 16.

The next quarterly dividend is on par with the previous one. If Amgen will hold it constant, the current $1.32 per share quarterly cash distribution will result in a 12-month dividend of $5.28 for a forward yield of 2.82%. The forward dividend yield has been computed based on Amgen’s market value on the stock market, as of March 7.

With the second quarter dividend, Amgen will have distributed a trailing 12-months dividend of $4.94 for a current dividend yield of 2.63%. This is 0.84 percentage points higher than the Standard & Poor's 500 dividend yield of 1.79%.

Amgen is dispersing part of its free cash flow to the holders of the stock based on a 171% pay-out ratio, which is abnormally beyond the industry median of 28%. However, financial solidity speaks loud at Amgen with $41.68 billion in cash on hand and securities, or $57.84 per share, and with $8.5 to $9 billion of levered free cash flow. The portion of levered free cash flow is about 75% of the cash flow Amgen can generate from its operations in a 12-month period.

The operating cash inflow that Amgen will use to support the dividend payment, will be determined by earnings that analysts predict to be $3.46 (+5.8% year over year) per share of the company on a quarterly revenue projected at $5.71 billion (-1.6% from fiscal 2017).

The debt to equity ratio is 140.02%. However, the interest coverage is 11.84. This is well above the 1.5 threshold that investors believe to be the borderline between the company with and without problems in paying the interest expenses on the outstanding debt.

Amgen is currently at $187.53 per share traded on the Nasdaq stock exchange. As of March 7, the healthcare stock has a market capitalization of $135.13 billion.

The stock – as illustrated in the Yahoo Finance’s chart – gained nearly 5.5% for the 52-weeks through March 7, however, its performance has been beaten by the S&P 500. The index gained 15.4% over the same span of time.

Source: Yahoo Finance

Amgen is trading above the 200, 100 and 50-SMA lines. The 52-weeks range is $152.16 to $201.23 per share.

The relative strength indicator (14-days) is 55.69 of a 20 to 80 range.

Amgen has a price-book ratio of 5.37 versus an industry median of 4.20 times and a price-sales ratio of 6.03 versus an industry median of 11.11 times.

The PE ratio is 70.77 times versus an industry median of 28.26 times. The forward PE ratio is 14.18 that, multiplied by a weighted (quarters) average of $13.57 for full fiscal years 2018 and 2019, yields to a value of $192.46 per share of Amgen. The average target price is $196.27 per share, and the recommendation rating is 2.4 out of 5.

As of March 2018, 15 analysts out of a total of 25 recommend holding shares of Amgen, while 10 analysts are for a buy to strong buy investing approach.

The Vanguard Group, Inc., leads the top institutional holders’ ranking with 7.26% of total shares outstanding of Amgen.

The Vanguard Group, Inc. is followed by FMR, LLC with 7.20% and Capital Research Global Investors with 7.07%. These figures are as of Dec. 30, 2017.

(Disclosure: I have no position in Amgen.)

About the author:

Alberto Abaterusso
If somebody asks what being a Value Investor means, Alberto Abaterusso would answer: “the Value Investor is not the possessor of a security that represents the company, but he is the owner of that company. As an owner of the company the Value Investor is actively involved in the dynamics of that company and his first aim is how to have sales progressively growing.”

Alberto Abaterusso would add: “probably the Value Investor is one of the least patient persons in the world concerning sales.”

Alberto Abaterusso is a freelance writer based in The Netherlands. He primarily writes about gold, silver and precious metals mining stocks. His articles have also been widely linked by popular sites, including MarketWatch, Financial Times, 24hGold, Investopedia, Financial.org, CNBS, MSN Money, Zachs, Reuters and others. Alberto holds an MBA from Università degli Studi di Bari (Italy), Aldo Moro.

Rating: 0.0/5 (0 votes)


Please leave your comment:

Performances of the stocks mentioned by Alberto Abaterusso

User Generated Screeners

cspunarHi ROA Lo Debt Div
pbarker46Owner earnings and FCF
DBrizanCDN2018dec11 10p
rmlkasuperROD 1
mjspencerpredictable but down 1m
wilhelmstone10yr div gainer
DBrizanall 2018dec09 1048p
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat